Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > August 8, 2022
Daily News
August 8, 2022
- Single-Wholesaler Distribution Unlikely to Constitute Antimonopoly Law Violation: Expert
August 8, 2022
- Kyowa Kirin Chief Sees Late-Stage Assets as Next Japan Biz Drivers, Room for Growth for Duvroq/Crysvita
August 8, 2022
- Eisai’s Q1 Operating Profit Drops 86% on Upfront Payment Receipt in FY2021
August 8, 2022
- E Keppra Now Eligible for Health Coverage for Status Epilepticus
August 8, 2022
- No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
August 8, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- Sosei’s Schizophrenia Med Advancing into PII, Triggers US$30 Million from Neurocrine
August 8, 2022
- Eisai on Track towards Lecanemab PIII Readout by Sept.-End, Japan/US/EU Filing by March 2023
August 8, 2022
- LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…